# Risankizumab

## Skyrizi inj 150mg/1mL

##### 臨採

| TAH Drug Code      | [ISKY1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISKY1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Psoriasis** Indicated for the treatment of adults with moderate to severe plaque psoriasis who are appropriate candidates for systemic therapy. 2. **Psoriatic Arthritis** Used alone or in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response to, or are intolerant to, disease-modifying antirheumatic drugs (DMARDs). 3. **Palmoplantar Pustulosis** Indicated for the treatment of adults with moderate to severe palmoplantar pustulosis who have not responded to or are intolerant to traditional therapies. 4. **Crohn's Disease** Indicated for the treatment of patients aged 16 years and older with moderate to severe Crohn's disease who have had an inadequate response to, lost response to, are intolerant to, or are not suitable candidates for traditional treatments or biologic therapy. 5. **Ulcerative Colitis** Indicated for the treatment of adults with moderate to severe active ulcerative colitis who have had an inadequate response to, lost response to, or are intolerant to traditional or biologic therapies. |
| Dosing             | Psoriasis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Psoriatic Arthritis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Palmoplantar Pustulosis: 150 mg subcutaneous injection at week 0, week 4, then every 12 weeks. Crohn’s Disease: Induction (IV formulation): 600 mg IV at week 0, week 4, and week 8. Maintenance (SC formulation): For responders to induction, 360 mg SC at week 12 and every 8 weeks thereafter. The safety and efficacy of Skyrizi have not been established for (1) Psoriasis, psoriatic arthritis, or palmoplantar pustulosis in patients under 18 years. (2) Crohn's disease in patients under 16 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | History of serious hypersensitivity reaction to risankizumab or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common: Injection site disorder (1.5-5.6%), Tinea (1.1%), Dyslipidemia, Abdominal pain (5.8-8.5%), Anemia (4.5-4.9%), Antibody development (3.4-24%), Arthralgia (5-9.2%), Arthropathy (0.6-3.5%), Backache (1.9-4.2%), Headache (3.5-6.6%), Urinary tract infectious disease (0.6-3.5%), Upper respiratory infection (10.6-13%), Fatigue (2.5%), Fever (2.6-4.9%). Serious: Injury of liver, Anaphylaxis, Hypersensitivity reaction (2.3%), Tuberculosis, Infectious disease (22.1-36.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/risankizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

